AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01973439 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention 2: PK assessment while on Once Daily Abacavir
Description: Week 4
Study NCT01445782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115
Description: Multiple dose, oral inhalation (nebuliser solution)
Study NCT01445782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose, oral inhalation (nebuliser solution)
Study NCT03270657 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IPG; RC+S
Description: We will measure the effects of varying stimulation parameters on the neural activity in subjects with Parkinson's disease (PD).
Study NCT02056171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
Study NCT02056171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
Study NCT02381080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
Study NCT02381080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
Study NCT02381080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
Study NCT03218111 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MR Imaging
Description: All subjects will undergo six sessions of MR imaging over a 10-12 hour period
Study NCT03218111 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CT-guidance
Description: All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
Study NCT01700179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0143102
Study NCT01700179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT00679341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine [Kadcyla]
Description: The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
Study NCT00679341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
Study NCT00679341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel was given at a dose of 75 or 100 mg/m\^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
Study NCT00779454 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine, Oxaliplatin, Capecitabine,
Description: Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
Study NCT00779454 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine
Description: Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
Study NCT01455324 — intervention group
Intervention type: DEVICE
Intervention: Novel conformable woven inner socket
Description: Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
Study NCT00002495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 25 mg/m\^2 on days 1 and 15
Study NCT00002495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 6 mg/m\^2 on days 1 and 15
Study NCT00002495 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard subtotal nodal irradiation
Description: 3600-4000 cGy delivered over 20 fractions
Study NCT01567189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: * Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.~* Health education sessions and relaxation sessions: one per week.~* Smoking and diet checking: as recommended by doctor.
Study NCT01567189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
Study NCT01509794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Valence
Description: Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
Study NCT01509794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Valence
Description: Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
Study NCT03917693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phytin, rice extract
Description: Consumption of a rice extract, called phytin for a period of 2 weeks
Study NCT03917693 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MCC, placebo
Description: Consumption of MCC, a placebo, for a period of 2 week
Study NCT01164852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delivery
Description: Termination of pregnancy (delivery)after completed corticosteroids
Study NCT01406691 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Flashes
Description: one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime
Study NCT01406691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flashes
Description: one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime
Study NCT02544893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: 21 ml 0.5 %bupivacaine is applied paravertebral space
Study NCT02544893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidin
Description: 1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
Study NCT02544893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: serum physiologic
Description: 21 ml serum physiologic is applied paravertebral space
Study NCT00879671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lutamax (leutein)
Description: leutein 20 mg for 3 months, then lutein 10 mg
Study NCT00879671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules identical in taste and appearance
Study NCT02517905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Local administration
Study NCT02517905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local administration
Study NCT03135522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Acetate 50 Mg Oral Capsule
Description: * Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~* Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~* Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)
Study NCT03135522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: * Day 0 (randomization) to day 3 Placebo (one capsule per day)~* Day 4 to day 7 If well tolerated: placebo (two capsules per day)~* Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)
Study NCT01678534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic mesenchymal stem cells from adipose tissue
Study NCT01678534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04546854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appeals
Description: Written text motivating participants to take up the seasonal influenza vaccination
Study NCT03258372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
Study NCT02309281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: aflibercept 2mg
Description: Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
Study NCT01114516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin and antibiotics (cefazolin or clindamycin)
Description: q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
Study NCT03211741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab Injection [Avastin]
Description: Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
Study NCT04090814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeatTens (HV-F311-E)
Description: (1) 2\~108 Hertz (modulation program inside); (2) 100 microseconds (pulse duration)
Study NCT01839708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The intervention will determine the differential outcomes of reading generic materials versus viewing custom DVDs containing targeted health information and discussions with MI-trained moderators on weight gain prevention.
Study NCT03102606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
Study NCT03102606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Study NCT03102606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration
Study NCT03102606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D5W Placebo
Description: Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
Study NCT05471999 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: interventional or surgical treatment
Study NCT00218023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase I.
Study NCT00218023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Description: Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase I.
Study NCT00218023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl
Description: Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase I.
Study NCT00218023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.
Study NCT04742595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
Description: Given IV
Study NCT03495752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bruce Fatigue Protocol
Description: Participant will perform the Bruce protocol as a fatigue stimulus to examine the impact of fatigue on the FSDT
Study NCT06425601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIL drain
Description: Silicone chest tube used for pleural space drainage after VATS lobectomy
Study NCT06425601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC drain
Description: Polyvinyl chloride chest tube used for pleural space drainage after VATS lobectomy
Study NCT01299428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INVOS 5100
Description: INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
Study NCT03184402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1252
Description: tablet
Study NCT03184402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gasmotin
Description: tablet
Study NCT03184402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Gasmotin
Description: tablet
Study NCT03184402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of DWJ1252
Description: tablet
Study NCT03172715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locking plate
Description: Osteosynthesis
Study NCT03172715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKR
Description: Total knee arthroplasty
Study NCT02087462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electroacupuncture (EA)
Description: Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks.
Study NCT02087462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Description: Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks.
Study NCT00218023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: The primary goal of motivational interviewing (MI) was to assist patients in achieving initial abstinence by increasing motivation and commitment to change. The MI intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I. The client-centered, MI-style sessions focused on building motivation for change, exploring ambivalence, obtaining a commitment to change, making a plan for abstinence (Session 1), providing personalized feedback, reassessing commitment for change, and reevaluating the change plan (Session 2). Masters-level therapists were trained and supervised by the therapy supervisor (ALS), an expert in motivation-based therapies.
Study NCT00440193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
Study NCT00440193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin followed by VKA
Description: Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
Study NCT04278872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJX-653
Description: administered orally once daily
Study NCT04278872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally once daily
Study NCT02087462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traction
Description: An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
Study NCT02087462 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Voltaren
Description: Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks.
Study NCT02087462 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin B1
Description: Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks.
Study NCT04309435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-esteem intervention
Description: See relevant study arm for description
Study NCT04309435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-stigma intervention
Description: See relevant study arm for description
Study NCT04309435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jumping to conclusions intervention
Description: See relevant study arm for description
Study NCT04309435 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control procedure (assessment only)
Description: See relevant study arms for description
Study NCT03793309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral vitamin D
Study NCT00431249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol
Study NCT00583427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: 200 mg per day in an oral gelcap form
Study NCT02526017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: Solution for IV administration
Study NCT02526017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Solution for IV administration
Study NCT05219032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Medical Interpreter
Description: A professional medical interpreter accompanies patient to each appointment.
Study NCT04540315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MobiMD
Description: MobiMD is a mobile app. This is an app available to IOS and Android devices only. The app provides a digitized version of the discharge instructions and provides push notifications to remind the participant of important instructions. In addition, the app allows participants (and their care teams) to record and track relevant clinical data.